Precigen (Nasdaq:PGEN) - Stock Price, News & Analysis

PGEN Stock Overview

Operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.

About the company

PGEN fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 95.3% below our estimate of its fair value

Earnings are forecast to grow 58.15% per year

Risk Analysis

Has less than 1 year of cash runway

Precigen, Inc. Competitors

XOMA

NasdaqGM:XOMA

US$297.8m

Actinium Pharmaceuticals

NYSEAM:ATNM

US$294.6m

Mereo BioPharma Group

NasdaqCM:MREO

US$414.5m

uniQure

NasdaqGS:QURE

US$238.1m

Price History & Performance

Summary of all time highs, changes and price drops for Precigen
Historical stock prices
Current Share Price	US$1.44
52 Week High	US$1.88
52 Week Low	US$0.84
Beta	1.77
1 Month Change	2.86%
3 Month Change	0.70%
1 Year Change	17.07%
3 Year Change	-77.85%
5 Year Change	-69.36%
Change since IPO	-94.18%

Recent updates

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Apr 18

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Nov 10

Precigen names Rutul Shah as chief operating officer

Sep 21

Circling Back On Precigen

Aug 23

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Aug 10

Precigen Q2 2022 Earnings Preview

Aug 07

Precigen to sell Trans Ova Genetics for $170M upfront

Jul 05

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

May 10

The Prognosis On Precigen

Jan 05

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Dec 31

Broker Revenue Forecasts For Precigen, Inc. (NASDAQ:PGEN) Are Surging Higher

Aug 12

Precigen (NASDAQ:PGEN) Is Carrying A Fair Bit Of Debt

Jul 16

Time To Worry? Analysts Are Downgrading Their Precigen, Inc. (NASDAQ:PGEN) Outlook

Mar 03

What Kind Of Investors Own Most Of Precigen, Inc. (NASDAQ:PGEN)?

Feb 12

Shareholder Returns

	PGEN	US Biotechs	US Market
7D	8.3%	0.4%	1.0%
1Y	17.1%	5.4%	27.2%

Return vs Industry: PGEN exceeded the US Biotechs industry which returned 5.4% over the past year.

Return vs Market: PGEN underperformed the US Market which returned 27.2% over the past year.

Price Volatility

Is PGEN's price volatile compared to industry and market?
PGEN volatility
PGEN Average Weekly Movement	8.3%
Biotechs Industry Average Movement	11.2%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	2.9%

Stable Share Price: PGEN has not had significant price volatility in the past 3 months.

Volatility Over Time: PGEN's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1998	202	Helen Sabzevari	precigen.com

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification.

Precigen, Inc. Fundamentals Summary

How do Precigen's earnings and revenue compare to its market cap?
PGEN fundamental statistics
Market cap	US$345.81m
Earnings (TTM)	-US$96.91m
Revenue (TTM)	US$5.44m

66.8x

P/S Ratio

-3.8x

P/E Ratio

Is PGEN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PGEN income statement (TTM)
Revenue	US$5.44m
Cost of Revenue	US$54.28m
Gross Profit	-US$48.84m
Other Expenses	US$48.07m
Earnings	-US$96.91m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.38
Gross Margin	-898.00%
Net Profit Margin	-1,781.72%
Debt/Equity Ratio	0%

How did PGEN perform over the long term?

See historical performance and comparison

PGEN Stock Overview

Rewards

Risk Analysis

Precigen, Inc. Competitors

NasdaqGM:XOMA

US$297.8m

NYSEAM:ATNM

US$294.6m

NasdaqCM:MREO

US$414.5m

NasdaqGS:QURE

US$238.1m

Price History & Performance

Recent News & Updates

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q1, 2024 Results on May 14, 2024

Price target decreased by 27% to US$6.50

Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy

President exercised options and sold US$575k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Recent updates

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q1, 2024 Results on May 14, 2024

Price target decreased by 27% to US$6.50

Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy

President exercised options and sold US$575k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Precigen: RRP Targeting With AdenoVerse Technology Platform

Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Independent Director recently sold US$136k worth of stock

Forecast to breakeven in 2026

Consensus revenue estimates fall by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Independent Director recently bought US$688k worth of stock

Consensus revenue estimates decrease by 12%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

President exercised options and sold US$58k worth of stock

Precigen, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Precigen, Inc. Receives Breakthrough Therapy Designation for PRGN- 2012 Adenoverse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc. to Report Q1, 2023 Results on May 10, 2023

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Precigen, Inc. Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

Insufficient new directors

Price target increased to US$14.50

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Precigen, Inc. Appoints Rutul R. Shah as Chief Operating Officer, Effective October 1, 2022

Precigen names Rutul Shah as chief operating officer

Chief Financial Officer recently bought US$51k worth of stock

Circling Back On Precigen

Independent Director recently sold US$115k worth of stock

Consensus revenue estimates fall by 66%

Independent Director notifies of intention to sell stock

Price target decreased to US$12.00

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen Q2 2022 Earnings Preview

Price target increased to US$13.75

Precigen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

URUS Group LP agreed to acquire Trans Ova Genetics LC from Precigen, Inc. (NasdaqGS:PGEN) for $180 million.

Precigen to sell Trans Ova Genetics for $170M upfront

President exercised options and sold US$211k worth of stock

Consensus revenue estimates increase by 21%

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Precigen, Inc. Announces Impairment of Goodwill for Three Months Ended March 31, 2022